Articles tagged with Prostate Cancer
Research found that men taking abiraterone or enzalutamide plus hormone therapy had a higher risk of metabolic and cardiovascular issues than those undergoing hormone therapy alone. This increased risk was observed in patients with Medicare health insurance, who were significantly older than those in clinical trials.
A large-scale study has found that men with prostate cancer have a 50% higher risk of developing serious and potentially fatal blood clots during the five years after their diagnosis. This increased risk is significant because venous thromboembolism (VTE) is a leading cause of death among people with cancer.
Researchers at USC have developed an innovative treatment for prostate cancer, known as synthetic immune receptor (SIR-T) therapy, which has shown promising results in preclinical studies. The new technology was adapted from CAR-T therapy and aims to revolutionize the treatment of not only prostate cancer but also other cancers.
Researchers developed a biosensor using nanostructured and nanoporous surfaces to detect biomarkers in clinical samples, overcoming technical challenges of small sample amounts. The new technology can provide quick and accurate diagnoses for diseases like prostate cancer without needing dilution or preprocessing steps.
Research suggests that PSA screening can prevent a significant number of prostate cancer deaths, with lower numbers than previously estimated. The study's findings support the benefits of PSA screening, especially for young healthy men and Black men, who have historically been underrepresented in clinical trials.
New research suggests that PSA screening has remarkably favorable tradeoffs, particularly for Black men, who disproportionately bear the burden of prostate cancer mortality and morbidity. The study's findings support the use of PSA screening for high-risk groups, including Black men, and highlight the need to revise clinical guidelines...
Researchers identified genetic patterns in brain metastatic prostate cancer cells, revealing potential targets for PARP inhibitor therapy. This study contributes to precision medicine by tailoring treatment to individual patient profiles.
A large population study found that smoking increases the risk of dying from prostate cancer, regardless of tumor stage, and is associated with a poorer prognosis. Smokers have a lower risk of developing prostate cancer but are more likely to be diagnosed at an advanced stage.
A recent study published in BMC Medicine found that obesity is associated with an increased risk of fatal prostate cancer. For every 10cm (four inches) on the waist, the risk of fatal disease increases by 7%. The study analyzed data from over 2.5 million men and found a link between body fat and prostate cancer risk.
Canada's cancer rates are declining overall, but new cases and deaths are on the rise due to an aging population and growing numbers. Despite this, efforts in cancer prevention, screening, early detection, and treatment have led to improved survival rates for those diagnosed with cancer.
The S1216 study showed an unprecedented median OS of 70 months in the control arm, outperforming previous results by 24 months. This extended survival was attributed to additional life-prolonging treatments patients received after completing the trial therapy.
Researchers at Cedars-Sinai have developed an AI tool that accurately predicts pancreatic cancer patients based on CT scan images. Lowering blood cholesterol has also been shown to slow the growth of prostate cancer by enhancing immune cell action. Additionally, a new study found that an ultrasound probe plugged into a smartphone can b...
The joint guide provides a framework for establishing theranostic centers globally, focusing on safety protocols and operational procedures. It highlights best practices for radiation protection, storage, administration, and other topics to improve patient care.
Research from Weill Cornell Medicine found that less prostate cancer screening has reduced overdiagnosis, but increased incidence of high-grade and metastatic disease. The study analyzed over 438,000 men with newly diagnosed prostate cancer between 2010 and 2018.
Researchers at Memorial Sloan Kettering Cancer Center have obtained exquisite views of the androgen receptor using cryo-electron microscopy. The study reveals unique features of the receptor that enable it to turn on a wide range of genes, distinct from other hormone receptors. This newfound understanding provides clues to how androgen...
Researchers have found that treating prostate cancer cells with novel CDK8 and CDK19 inhibitors reduces their potential to migrate into surrounding structures. This suggests a promising approach to overcome resistance against anti-androgenic therapy, offering new therapeutic options for patients with advanced disease.
Researchers identified rural Georgia counties with high mortality rates from breast, prostate, colorectal, and lung cancer. These hotspots were concentrated in the eastern Piedmont to southern Coastal Plain regions, as well as southwestern and northern rural areas.
A study suggests that accounting for genetic factors causing normal variations in PSA levels could improve the accuracy of prostate cancer detection. By analyzing data from over 95,000 men, researchers identified a polygenic score that accounted for 7.3-8.7% of variation in baseline PSA levels and was not associated with prostate cancer.
A study of 51,000 US veterans found a significant decrease in prostate cancer biopsies and diagnoses during the COVID-19 pandemic, with no racial disparity observed. The results suggest that the pandemic may have had a protective effect on prostate cancer diagnosis rates among Black and White veterans.
A novel nuclear medicine combination therapy combining <sup> 177 </sup> Lu-PSMA-617 with idronoxil (NOX66) has been shown to be safe and effective in reducing PSA levels by over 50% in men with metastatic prostate cancer. The median overall survival was 19.7 months, suggesting potential for improved patient outcomes.
A novel high-throughput screening assay has been developed to identify inhibitors of the androgen receptor, which plays a critical role in prostate cancer progression. The assay could lead to new treatments for resistant forms of prostate cancer.
Researchers at the University of Illinois Chicago are studying licorice-derived substances for their potential to prevent or stop prostate cancer growth. The study suggests that these compounds, such as glycyrrhizin and its derivatives, may have anti-inflammatory and anti-cancer effects.
Patients with serious illnesses seek cosmetic procedures to maintain their physical and mental well-being, as well as to become comfortable in social settings. The study found that these procedures are often chosen for noninvasive treatments and endorsed by doctors, friends, and family.
A study by MedUni Vienna reveals that mutations in the KMT2C protein lead to increased cell division, driving metastatic prostate cancer. This discovery may enable early diagnosis through a blood test and treatment with MYC inhibitors.
A new radiotracer containing zirconium-89 has significantly improved the accuracy of detecting localizing prostate cancer relapses. The technique allows for earlier treatment using precise radiation therapy, increasing patient survival rates.
Researchers found that adjuvant radiation therapy compared to early salvage therapy reduced mortality risk in men with pN1 prostate cancer. The study, published in the Journal of Clinical Oncology, showed a 8% decrease in mortality for each additional positive pelvic lymph node found at surgery.
A study from Keck Medicine of USC found a significant increase in metastatic prostate cancer cases among men 45 and older, coinciding with the end of routine screenings. The incidence rate rose by 41% in men 45-74 and 43% in men 75 and older.
A novel radioligand therapy has been shown to increase progression-free survival (PFS) and overall survival (OS) of metastatic castration-resistant prostate cancer (mCRPC) patients. Ninety-one percent of patients experienced a greater than 50% reduction in PSA values after treatment, with a median PFS of 22 months.
A new study developed an algorithm estimating a person's risk of developing prostate cancer based on age and two prostate cancer markers. The approach was found to reduce the number of false positives by three quarters compared to a standard PSA test while catching the same proportion of cancers, making screening safer and more accurate.
A study of nearly 40,000 Medicare beneficiaries found racial disparities in the use of MRI among Black and white patients with new prostate cancer diagnoses. The study identified factors such as insurance coverage, socioeconomic status, and geographic location that contribute to these disparities.
A study of over 2,700 men with localized prostate cancer found that initial treatment choice didn't affect depression or emotional well-being. However, factors such as age, overall health, and initial depressive symptoms were linked to declines in mental health outcomes.
Researchers at Toyohashi University of Technology developed a microchip capable of detecting ultra-low concentrations of prostate cancer antigens using flexible nanosheets. The chip's lower detection limit is comparable to that of large testing devices, enabling fast and accurate diagnosis.
Cedars-Sinai investigators discover that inhibiting RIPK2 function with drugs or CRISPR/Cas9 reduces prostate cancer metastasis in mice, offering new hope for advanced prostate cancer treatment. Targeting this protein could extend patients' lives by several years.
A supervised exercise program can reduce anxiety and fear of cancer progression in men undergoing active surveillance for prostate cancer. The study found significant improvements in mental and physical health benefits, including a reduction in prostate cancer-related anxiety and fear of progression.
A phase 3 trial demonstrates that adding darolutamide to standard therapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer. The treatment also delays disease progression and reduces need for additional therapies.
Researchers developed patient surrogates to evaluate potential prostate cancer treatments, identifying genes that could be targeted with drugs. The models predicted synergistic effects of treatments and identified promising drug combinations.
Researchers have identified an antibody drug that significantly improves survival rates in pet dogs with advanced prostate cancer. By targeting regulatory T cells, the treatment may offer a new hope for patients with this devastating disease.
A recent study reveals that Black and Latinx men are severely underrepresented in online prostate cancer resources. The study found that only 9% of people depicted in online content were Black or Latinx, highlighting the need for greater representation and diversity in health education.
A novel blood test, Stockholm3, in combination with MRI reduces overdiagnosis of low-risk cancers by 60% and unnecessary biopsies by 9%. This cost-effective approach is recommended for Sweden's organized prostate cancer testing (OPT) pilot projects.
A new analysis links genetic variants associated with high blood levels of lipoprotein A to a higher risk of prostate cancer, including advanced or early-age-onset cases. The study found no significant associations for other blood lipids.
A recent study has found that faulty versions of the BRCA1 and BRCA2 genes are associated with an increased risk of developing prostate and pancreatic cancers in men. The study analyzed data from over 3,200 families and estimated that men who carry a BRCA2 mutation have a 27% risk of developing prostate cancer by age 80.
A UCLA-led meta-analysis of individual patient data from three cohorts found that patients receiving high-dose external beam radiation therapy alone may benefit from longer androgen deprivation therapy (ADT) durations, while those with external beam radiation therapy and brachytherapy boost may be optimally managed with shorter ADT. Th...
A new study confirms the accuracy of the European Association of Urology (EAU) risk classification system for prostate cancer patients, using PSMA PET imaging to identify subgroups with varying disease risks. High-risk groups showed higher metastatic disease rates, while low-risk groups had undetectable or distant metastases.
A new meta-analysis of randomized clinical trials found that adding androgen deprivation therapy (ADT) to definitive radiotherapy prevents one cancer from metastasizing for every 10 to 15 men treated. Prolonging adjuvant ADT also showed significant benefits, while neoadjuvant ADT was not effective beyond two months.
A newly identified molecular signal can spot aggressive tumor cells in early prostate cancers, allowing for targeted treatment. Researchers at Duke University Medical Center have developed a test to guide treatment based on this genomic signature.
A recent analysis of 7.8 million VA patients found significant disparities in localized and metastatic prostate cancer incidence between African Americans and whites. The study highlights the need for targeted interventions to address racial gaps in prostate cancer care.
A recent study by Moffitt researchers found that African American veterans had a significantly higher incidence of prostate cancer compared to European American men. The study also revealed that timely treatment and clear documentation are crucial in reducing the risk of metastasis among African American men.
A meta-analysis published in The Lancet Oncology reveals that men with intermediate- and high-risk prostate cancer experience improved overall survival with the addition of hormone therapy to radiotherapy. The study found prolonged adjuvant hormone therapy benefits men, while neoadjuvant hormone therapy did not.
A large international evaluation shows AI systems can identify and grade prostate cancer in tissue samples from different countries equally well as human pathologists. The results suggest AI can be a complementary tool in prostate cancer care, improving diagnostic quality and consistency.
Researchers aimed to tackle racial disparities in prostate cancer by targeting educational interventions to populations at highest risk. A study in Philadelphia neighborhoods found that prostate-specific education improved knowledge and intention to screen, with similar effects on control groups.
A UCI-led team identified a molecular feature in prostate cancer associated with ancestry, which may help predict patient risk and tailor treatment. ERV expression signatures also showed promise for identifying patients at greatest risk of progression across different ancestries.
The Society of Nuclear Medicine and Molecular Imaging has published appropriate use criteria (AUC) for prostate-specific membrane antigen (PSMA) PET imaging. The guidelines provide a framework for healthcare providers to determine the most effective use of PSMA PET scans in patients with suspected or known prostate cancer.
A portable prostate cancer screening kit could provide early warning to populations with higher incidence of prostate cancer, particularly African American men. The test uses a test strip and reader to quantify PSA from a drop of blood in minutes, delivering results in 10-15 minutes.
The study combined seven randomized clinical trials with 8,000 patients to compare overall and treatment-specific outcomes of Black and white men with localized prostate cancer who received radiation therapy. The results showed that there were significant racial disparities in response to radiation therapy for prostate cancer.
A meta-analysis of seven randomized trials found that Black men with localized prostate cancer had lower recurrence, metastasis, and mortality rates compared to white men. The study challenges the common belief that Black men with prostate cancer have a worse prognosis.
Researchers discover a chromatin degrader that blocks cancer-causing genes, offering potential treatment for over 90% of prostate cancers. The study found that blocking the SWI/SNF complex slowed cancer cell growth and induced cell death, especially in tumors driven by FOXA1 or androgen receptor.
Researchers have identified NDUFS1 and ATP5O as novel markers of aggressive prostate cancer, associated with poorer survival rates. The study's findings provide new insights into the disease's molecular mechanisms and potential targets for therapy.
A clinical study and register studies have failed to confirm previous findings that a medicine blocking testosterone could help against COVID-19. The researchers found no discernible signs of the drug having any beneficial effect on participants' health status.
Surgeons at Henry Ford Health performed the world's first precision prostatectomy through the bladder using a single port robotic surgical system. The procedure preserves a portion of the prostate capsule, improving functional outcomes such as erectile function and urinary control.
A study found that men with Li-Fraumeni syndrome have a 25-fold increased risk of developing aggressive prostate cancer, and those with inherited TP53 variants are diagnosed at a young age. Routine screening for prostate cancer is recommended for these individuals.